Breaking tolerance to invoke an immune response to cancer
Upcoming SlideShare
Loading in...5
×
 

Breaking tolerance to invoke an immune response to cancer

on

  • 627 views

 

Statistics

Views

Total Views
627
Views on SlideShare
627
Embed Views
0

Actions

Likes
0
Downloads
6
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Breaking tolerance to invoke an immune response to cancer Breaking tolerance to invoke an immune response to cancer Document Transcript

  • Breaking Tolerance to Invoke an Immune Response to Cancer (Melanoma)Introduction:This paper is dedicated to all the Melanoma Patients that aren’t here today but wereinstrumental in this research through all the clinical trials.I have postulated that the T Regulatory Cells (Treg) may be the major stumblingblock in the whole immunotherapy response rate. Recent studies have shown that CD4+CD25high FoxP3+ Treg cells areoverrepresented in human metastatic lymph nodes with a 2-fold increased frequencycompared with both tumor-free lymph nodes and that advanced melanoma isassociated with increased numbers of circulating Treg cells and Dendritic Cells(DCs) and suggested that melanoma induces immunosuppressive DCs and Treg cellsin the systemic circulation of the patients . Vence et al also showed the presence oftumor antigen-specific CD4+ Treg cells in the blood of patients with metastaticmelanoma.This means the host (you) may already have the correct antigen, but the tumor andmicroenvironment may be suppressing the immune response by secretingsuppressive cytokines like TGF- beta , IL-10, and IL -6 and or proliferating thesuppressive Tregs. Nicholaou et al most recently showed in patients with melanoma that althoughstrong antibody responses were mounted, the generation of delayed-typehypersensitivity response was significantly impaired and patients with advancedmelanoma had a significantly higher proportion of circulating CD4+ CD25+ 1
  • FoxP3+ Treg cells compared with those with minimal residual disease. So we nowcan blame the tolerance of our immune system to cancer on the T Regulatory Cells(Tregs).It has been reported that the large number of different cell types that are claimingto be directly targeted by FoxP3+ Treg cells are CD4+, CD8+ T cell, dendriticcells, B cells, macrophages, osteoblasts, mast cells, NK cells, and NKT cells.If this is the case we must temporality deplete or suppress the T- Regulatory Cells(Tregs). This can be accomplished in a number of ways. Dr. Steven A Rosenberg usesCyclophosamide. This is accomplished by administering the drug prior to ACTTherapy.Another way to suppress the Treg function is to block the CTLA-4 receptor with anantibody. That antibody, known as Anti-CTLA-4, Yervoy (Ipilimumab) that wasFDA approved in March of 2011. 2
  • Patients treated with Anti-CTLA-4 showed a statistically significant decrease in themedian percentage of Treg cells by Day 28 of therapy (5.8% vs.3.6%) “Biologic andImmunomodulatory Events after CTLA-4 Blockade with Ticilimumab in Patientswith Advanced Malignant Melanoma” et al Luis H. Camacho 2006.Also, after treatment the treated patients had a significantly higher median percentage ofresting CD4_CD25_ T cells that coexpressed PD-1 compared with control subjects(66.4% vs. 25.0%). This mean the Anti-CTLA-4 therapy unregulated the PD-1 on restingT-cells. This is an unwanted effect, the upregulation PD-1 is known to cause T-cellexhaustion. This is why the combination of Anti-PD-1 and Anti-CTLA-4 would be amore synergistic treatment for Melanoma.<A HREF="https://www.box.net/s/mzxb1b2o0tue44a3z3xo">Breaking Tolerance toInvoke an Immune Response to Cancer (Melanoma</A> <BR> 3
  • CTLA-4 blockade therapy can succeed in breaking peripheral immune tolerance in somepatients, but not in others. So what are we missing? We removed the suppressive functionof the Tregs. We believe we have tumor specific antigens. What is the one thing thathappens with most immune responses? The “DANGER SIGNAL”. You get aninflammatory response. 4
  • Proflammatory Cytokines and chemoattractants must be induced to produce an immuneresponse. If not, the immune response doesn’t take hold and it (the response) isterminated.Now with this information, we now know that we need Proflammatory Cytokines andchemoattractants to initiate an immune response. Recently, in a paper by Dr. Thomas F.Gajewski, “Identifying and Overcoming Immune Resistance Mechanisms in theMelanoma Tumor Microenvironment” 2006, he states:"Immunotherapeutic approaches for the treatment of melanoma, such as tumor antigen-based vaccines, can frequently boost immune responses. However, clinical responses asmeasured by tumor shrinkage are seen in only a minority of patients. This observation hasprompted careful analysis of the tumor microenvironment for biologic correlates toclinical response and also to identify mechanisms of tumor resistance. Patients withadvanced melanoma treated with antigen-specific vaccines had pre-treatment tumorbiopsies analyzed by gene expression profiling. Supervised hierarchical clustering wasperformed based on clinical outcome. An expanded bank of tumors was analyzed toincrease the sample size and better understand gene patterns.Two major categories of melanoma metastases have been observed.One subgroup of patient has an inflamed phenotype that includes expression ofchemokines, T-cell markers, and other immunoregulatory factors. Clinical responders tomelanoma vaccines appear to fall within this subset. This group also contains the highestexpression of negative regulatory factors, including PD-L1, IDO, and FoxP3, suggestingthat these immunosuppressive mechanisms may dominantly inhibit anti-tumor –cellfunction in those patients. In addition, absence of B7 expression supports classical T-cellanergy. Preclinical experiments have confirmed a critical role for these mechanisms inlimiting anti-tumor T–cell efficacy in vivo, giving candidate treatment strategies fortranslation back into the clinic.A second subset of patients is represented by tumors which are non-inflamed and lackchemokines for T cell recruitment. Therefore, a major barrier in these cases appears to befailed T –cell migration into tumor sites. Experimental strategies to augment T-cellmigration can have important anti-tumor effects in preclinical models. The presence ofthe "inflamed" gene signature was associated with a type I IFN transcriptional profile,and murine experimental models have confirmed a critical role for type I IFN signaling inpromoting adaptive immunity." 5
  • So, in the first subset of Patients, tumors had a suppressive nature that may be over-ridden by Anti-CTLA-4 (Yervoy) and or Anti-PD-1 Therapy.The second subset was missing the "danger signal" inflammatory cytokines andchemoattractants most likely due to STAT3 signaling from the Tumor. 6
  • Stimulation of Toll-like receptor 4 (TLR-4) activates macrophages and results in therelease of TNF-alpha. It is hypothesized that melanoma inhibits macrophage activationby suppressing TLR-4 signaling. 7
  • So, if Melanoma suppresses Macrophage Activation, then the tumor microenvironment ismissing IL-6, IL-1b and other cytokines and chemoattractants secreted by the Tumor-derived Antigen presenting cells (APCs) like the Dendritic Cells and Macrophages. 8
  • Activated Macrophages secrete the following cytokines under different conditions:IL-1, IL-12, IL-6, IFN-gamma/alpha/beta and TNF-alphaIL-6Interleukin 6 is a pro-inflammatory cytokine and is produced in response to infection andtissue injury. IL-6 exerts its effects on multiple cell types and can act systemically.IL-6 stimulates liver secretion of acute phase proteinsIL-6 stimulates B-lymphocytes to produce antibodiesIL-6 in concert with IL-1b causes T-cell activationIL-6 induces STAT 3 SignalingIL-6 Plus TGF-b induces the Th17 cell phenotypeIL-1 betaInterleukin-1b is a pro-inflammatory cytokine which is secreted by macrophagesactivated by a number of stimuli including TNF-alpha, bacterial endotoxin and IL-1b 9
  • itself.IL-1b exerts its effects on many different cell types locally at the site of production andsystemically (at a distance).IL-12Interleukin-12 is a heterodimer consisting of a p35 and a p40 subunit. Both subunits arerequired for receptor binding and biological activity.IL-12 stimulates growth of activated Natural Killer (NK) cells, CD8+ and CD4+ T- cells.IL-12 increases NK and T-cell g-IFN production which shifts T-cell differentiationtowards a Th1-type response.IL-12 increases NK production of TNF-alpha which can act synergistically with IFN-gamma.IL-12 suppresses IL-4 induced IgE production.TNF-alphaTumor Necrosis Factor alpha is made by many other cells as well as macrophages, whichare major sources, especially after priming by Interferon gamma.TNF-alpha initiates a cascade of cytokines which mediate an inflammatory response.TNF-alpha effects are mediated through two types of receptor, a 75kDa TNFR-a receptorand a 55kDa TNFR-b receptor.TNF-alpha regulates the expression of many genes in many cell types important for thehost response to infection.IFN-gamma/betaMacrophages, and many other cells produce these Type I interferons which act asimmunomodulatory, as well as antiviral cytokines. Distinct receptor from interferongamma, mediates overlapping or competing effects on macrophages. Cellular signalingpathways involve Jak/Stats, and other pathways.So, if Melanoma suppresses Macrophage Activation, then the tumor’s microenvironmentis missing IL-6, IL-1b and other cytokines. This change in the tumor’s microenvironmentresults in the suppression of the T- cell Activation. 10
  • If you look at the above micrographs, you will see that the two patients that had relapsed(10710 and 10737) had IL-1b and IL-6 missing. The macrophages were not activated!!!!The "Danger Signal" known as inflammation was missing! The non-responders mostlikely had their macrophages polarized to a M2-like phenotype. 11
  • 12
  • So what if you introduced a mixture of cytokines that resembles the secretion from theTumor derived APCs. Would you induce an immune response? This is just what a smallBiotech company; CEL-SCI Corporation is trying. It is now in Phase 3 clinical trials. It isused prior to therapy/radiation to enhance the immune system. 13
  • “As we look at data from Phase I and Phase II clinical trials, we see strongindication that Multikine simulates the activities of a healthy person’s immunesystem, enabling it to use the body’s own anti-tumor immune response.”What if there was another way to activate the immune system. Recent researchshows that if you use CpG ODNs (TLR9 antogonists) on mature dendritc cells,immune activation occurs. “Deoxycytidyl-deoxyguanosine [(CpG)3]oligodeoxynucleotides (ODNs) signal through TLR9 to induce innate immune responsesand adjuvant effects that promote T cell responses.” et al C. V. Harding and colleagues.CpG ODNs can be divided into three Classes. Class C, CpG-B&C ODNs stimulate Bcells efficiently to produce IgM and IL-6. This is very important because we want IL-6produced because IL-6 in concert with IL-1b causes T-cell activation.TLR9 signaling regulates multiple aspects of antigen processing and APC function. Inmice, TLR9 is widely expressed by APCs, including myeloid DCs (mDCs), pDCs,macrophages, and B cells. In humans, TLR9 expression is restricted to (pDCs)plasmacytoid DCs and B cells. CpG ODNs promote maturation of mDCs, which resultsin enhanced expression of MHC-I, MHC-II, and costimulatory molecules (i.e., CD40,CD80, and CD86) B7-1, B7-2 and increased MHC-I and MHC-II antigen-presentationfunction. 14
  • Activation of a T-cellAccording to Dr. Slingluff in a paper recently, he broke down the immunohistologicCharacteristics into three immunotypes.In the research paper “Immunotype and Immunohistologic Characteristics of TumorInfiltrating Immune Cells are Associated with Clinical Outcome in MetastaticMelanoma”1 et al Slingluff 2012, it breaks down the Immunohistologic Characteristicsinto three distinct immunotypes:A) No infiltration of immune cells in the tumor’s microenvironment.B) Infiltrating Immune cells only in close proximity to the tumor’s vascular systemC) Diffuse immune cell infiltrates throughout a metastatic tumor and its microenvironment. 15
  • Immunohistologic Characteristics of Tumor Infiltrating Immune CellsImmunotype A B CImmune cell None(very Low) Some ThroughoutinfiltrationEstimated median 15 23 130survival (months)Metastases (%) 29 63 8B-cells Low Med HighMacrophages High Med Lowlikely M1 or M2 M2 Mix M1CD8+ T-cells Low Med HighOverall, the most predominant immune cells were T cells (53%), followed by the B celllineage cells (33%), and then by macrophages (13%), with NK and mature dendritic cellsonly hardly present.With the setting of the tumor’s microenvironment evaluated, we will focus the low survivalimmunotype A patients. How can we improve the overall survival and the immune responseto Melanoma? We need to push the differentiation of the macrophages towards the M1phenotype.Macrophages are important tumor-infiltrating cells and play pivotal roles in tumor growthand metastasis. Macrophages participate in immune responses to tumors in a polarizedmanner: classic M1 macrophages produce interleukin (IL) 12 to promote tumoricidalresponses, whereas M2 macrophages produce IL10 and help tumor progression. Themechanisms governing macrophage polarization are unclear But in 1990 it wasdiscovered treatment of M2 macrophages with GM-CSF or IFN-gamma led toproduction of M1 phenotypic markers upon LPS stimulation. The research paper “IRF5promotes inflammatory macrophage 1 polarization and TH1-TH17 response” Et alIrina A. Udalova explains it in great detail.One of the hallmarks of M1 macrophage polarisation is acquired antigen presentingfeatures leading to efficient Th1 response. 16
  • The M1 macrophage phenotype is induced by Interferon gamma (IFN-γ) followed bystimulation with bacterial products like lipopolysaccharides (LPS) or by treatment ofmonocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF). Based onImmunohistologic Characteristics of Tumor Infiltrating Immune Cells presented by Dr.Slingluff, the macrophages in the A type (Non-responder) must be M2 phenotype. Since theMacrophage are known to have plasticity, one could in theory change theirmicroenvironment to shift the macrophages from M2 to M1 phenotype.We need to somehow combine these immunotherapies with a cancer vaccine to invoke animmune response using the macrophages as the starter of immunity with memories T-cells sowe can eliminate any reoccurrence.Oncologists have been working on this for decades. I believe they may have discovered the right combination to just that. Dr. Kingston Mills andcolleagues from the Immune Regulation Research Group, School of Biochemistry andImmunology, Trinity Biomedical Sciences Institute, Trinity College DublinImmunotherapy with PI3K Inhibitor and Toll-Like ReceptorAgonist Induces IFN-γ IL-17þ Polyfunctional T Cells ThatMediate Rejection of Murine TumorsDr. Mills and colleagues discovered that if you combine a PI3k inhibitor with TRL agonists(TRL9 and or 5) with DC vaccine/tumor antigen, you invoke a tremendous immune responsealong with memory cells. This is because this combination (PI3k inhibitor with TRL 17
  • agonists) induces IFN gamma which differentiates M2 macrophages into the M1 phenotypewhich in turn activates the Th1 effector T-cells.TLR agonists, including CpG ODNs, have been shown to break tolerance to self-antigensby inhibiting the function of Treg cells via the production of IL-6 by DC. However, CpGODNs have also been shown to stimulate the production of IL-10 by DC, and promotethe induction of Treg cells. Therefore, CpG ODNs can generate effector as well assuppressive immune responses well as suppressive immune responses.Immune activation by CpG ODN initiates with specific binding to the TLR9 receptor inB cells and plasmacytoid DCs. TLR9 ligation in DCs results in secondary activation oflymphocytes, macrophage, monocyte, NK-cell, and T-cell populations through theelaboration of cytokines generating a TH1 cytokine milieu. This results in increased NKactivity as well as improved antigen presentation and T cell help that can augmenthumoral and cell-mediated immune responses. In addition, TLR ligation results in theproduction of IL-6 by DCs, which helps overcome the suppressive effect of CD4 CD25Treg cells. 18
  • TLR9 signaling regulates multiple aspects of antigen processing and APC function. Inmice, TLR9 is widely expressed by APCs, including myeloid DCs (mDCs), pDCs,macrophages, and B cells. In humans, TLR9 expression is restricted to pDCs and Bcellset al H. Wagner. CpG ODNs promote maturation of mDCs, which results inenhanced expression of MHC-I, MHC-II, and costimulatory molecules (i.e., CD40,CD80, and CD86) and increased MHC-I and MHC-II antigen-presentation function et alC.V. Harding. With the addition of a PI3K Inhibitor, one can tilt the T-cell Differentiation toward theTh1 Phenotype and limiting the propagation of Tregs. This is a winning combination. Itnot only awakens the innate immune system, but also awakens the Adaptive ImmuneSystem which can mount an immune response with memory. A VACINATION in vivo.This approach uses the full arsenal of the immune system. 19
  • One also thinks if you add Yervoy and anti-PD-1 with TRL9 agonist you might alsoproduce the right immune response. This assumption needs to be tested with Clinicaltrials. 20
  • 21
  • 22
  • 22
  • 22